Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions from steatosis to cirrhosis and hepatocellular carcinoma. Steatosis is a benign reversible condition, which does not need treatment. Cirrhosis and hepatocellular carcinoma are the end stages of any chronic liver disease and do not have etiology-specific treatments. In this chapter, we will review treatment options for non-alcoholic steatohepatitis, which is the progressive form of NAFLD. Basically there are 2 strategies, the first of which is to address lifestyle and the second to use medication. The first approach is the most physiologic, the least expensive, but is also the most difficult to implement. The second approach, which should help patients who failed the first approach, is at the advanced clinical research stage.

1.
Suzuki A, Lindor K, St Saver J, et al: Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005;43:1060-1066.
2.
Harrison SA, Fecht W, Brunt EM, et al: Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009;49:80-86.
3.
Promrat K, Kleiner DE, Niemeier HM, et al: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-129.
4.
Huang MA, Greenson JK, Chao C, et al: One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-1081.
5.
Wong VW, Chan RS, Wong GL, et al: Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2013;59:536-542.
6.
Sullivan S, Kirk EP, Mittendorfer B, et al: Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012;55:1738-1745.
7.
Keating SE, Hackett DA, George J, et al: Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;57:157-166.
8.
St George A, Bauman A, Johnston A, et al: Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009;50:68-76.
9.
Hallsworth K, Fattakhova G, Hollingsworth KG, et al: Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011;60:1278-1283.
10.
Oh S, Shida T, Yamagishi K, et al: Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology 2015;61:1205-1215.
11.
Parker HM, Johnson NA, Burdon CA, et al: Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;56:944-951.
12.
Sanyal AJ, Abdelmalek MF, Suzuki A, et al: No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014;147:377-384.
13.
Bozzetto L, Prinster A, Annuzzi G, et al: Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 2012;35:1429-1435.
14.
Ryan MC, Itsiopoulos C, Thodis T, et al: The mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013;59:138-143.
15.
Machado MV, Ravasco P, Jesus L, et al: Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol 2008;43:95-102.
16.
Kechagias S, Ernersson A, Dahlqvist O, et al: Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008;57:649-654.
17.
Basaranoglu M, Basaranoglu G, Sabuncu T, et al: Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013;19:1166-1172.
18.
Abdelmalek MF, Suzuki A, Guy C, et al: Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1961-1971.
19.
Birerdinc A, Stepanova M, Pawloski L, et al: Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;35:76-82.
20.
Anty R, Marjoux S, Iannelli A, et al: Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012;57:1090-1096.
21.
Dunn W, Sanyal AJ, Brunt EM, et al: Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012;57:384-391.
22.
Liu Y, Dai M, Bi Y, et al: Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in china. J Epidemiol 2013;23:115-121.
23.
Hézode C, Roudot-Thoraval F, Nguyen S, et al: Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63-71.
24.
Kim CW, Yun KE, Jung HS, et al: Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses. J Hepatol 2013;59:351-357.
25.
Haedrich M, Dufour JF: UDCA for NASH: end of the story? J Hepatol 2011;54:856-858.
26.
Mahady SE, Webster AC, Walker S, et al: The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J Hepatol 2011;55:1383-1390.
27.
Singh S, Khera R, Allen AM, et al: Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 2015;62:1417-1432.
28.
Du J, Ma YY, Yu CH, et al: Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2014;20:569-577.
29.
Hoofnagle JH, Van Natta ML, Kleiner DE, et al; Non-Alcoholic Steatohepatitis Clinical Research Network (NASH CRN): Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013;38:134-143.
30.
Lavine JE, Schwimmer JB, Van Natta ML, et al; Nonalcoholic Steatohepatitis Clinical Research Network: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-1668.
31.
Lonn E, Bosch J, Yusuf S, et al; HOPE and HOPE-TOO Trial Investigators: Effects of long-term vitamin E supplementation on cardiovascular events and cancer. JAMA 2005;293:1338-1347.
32.
Klein EA, Thompson IM Jr, Tangen CM, et al: Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011;306:1549-1556.
33.
Pellicciari R, Fiorucci S, Camaioni E, et al: 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45:3569-3572.
34.
Modica S, Gadaleta RM, Moschetta A: Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 2010;8:e005.
35.
Lambert G, Amar MJ, Guo G, et al: The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003;278:2563-2570.
36.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al; NASH Clinical Research Network: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-965.
37.
Musso G, Cassader M, Gambino R: Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov 2016;15:249-274.
38.
Marra F, Tacke F: Roles for chemokines in liver disease. Gastroenterology 2014;147:577-594.e1.
39.
Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group: Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016;150:1147-1159.
You do not currently have access to this content.